Advertisement BD acquires right to negotiate Accelr8's diagnostic technology - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

BD acquires right to negotiate Accelr8’s diagnostic technology

Accelr8 Technology has reported that the Becton Dickinson and Company has purchased an exclusive right on to negotiate for a business relationship to develop Accelr8's BACcel rapid diagnostic platform.

The right grants to Becton Dickinson (BD) an exclusive discussion period through March 31, 2008 during which the companies will explore a possible product development relationship and definitive terms for such a relationship. If an agreement is reached, terms may include any of the elements or combination of elements of licensing, equity investment, joint development, or other mutually suitable product development and commercialization program. BD will pay Accelr8 $100,000 for the right.

David Howson, president of Accelr8, said: “BD recognizes the potential value of the BACcel system as a ‘fast front end’ that complements their automated culturing systems and gene analysis products.”